Actin depolymerization and inhibition of capping induced by pentoxifylline in human lymphocytes and neutrophils.
Pentoxifylline is used clinically for the treatment of intermittent claudication. It is believed to exert its effect by altering the rheologic properties of blood. The cytoskeleton plays an important role in the maintenance of cell structure and function. In particular, alterations in the state of actin seem to play an important role in cell motility. Therefore, we examined the effect of pentoxifylline on the actin state in human polymorphonuclear leukocytes (PMN) and mononuclear cells. Pentoxifylline (10 mM final concentration) decreased F-actin content in both PMN and mononuclear cells. Pentoxifylline also inhibited concanavalin A-induced capping in PMN and mononuclear cells. Similarly, surface immunoglobulin capping in B lymphocytes was also inhibited. Pretreatment of cells with pertussis toxin did not inhibit pentoxifylline-induced decrease in F-actin, suggesting pentoxifylline does not act through pertussis toxin-sensitive G-proteins. Dibutyryl cyclic AMP failed to show any significant effect on the F-actin content in PMN. Therefore, the effect of pentoxifylline cannot be attributed to changes in cyclic AMP levels. Chemotactic peptide-induced actin polymerization was unaffected in PMN when expressed as percent changes in F-actin. The observations reported here suggest that the rheological effects of pentoxifylline might be due to its effects on the actin state in the cellular elements of the blood. Further studies on the mechanism of action of pentoxifylline on actin state in leukocytes will prove useful in delineating the physiological mechanisms regulating actin state in leukocytes.
Rao
K M
KM
Geriatric Research, Education and Clinical Center, Veterans Administration, Medical Center, Durham, North Carolina 27705.
Crawford
J
J
Currie
M S
MS
Cohen
H J
HJ
D000199:Actins / Q000378:metabolism*; D003994:Bucladesine / Q000494:pharmacology; D006801:Humans; D007152:Immunologic Capping / Q000187:drug effects*; D008214:Lymphocytes / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000494:pharmacology; D009504:Neutrophils / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism; D010431:Pentoxifylline / Q000494:pharmacology*; D037342:Pertussis Toxin; D011108:Polymers; D013805:Theobromine / Q000031:analogs & derivatives*; D010566:Virulence Factors, Bordetella / Q000494:pharmacology
D000199:Actins; D011108:Polymers; D010566:Virulence Factors, Bordetella; D009240:N-Formylmethionine Leucyl-Phenylalanine; D003994:Bucladesine; D037342:Pertussis Toxin; D013805:Theobromine; D010431:Pentoxifylline